JP2006512357A - Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体 - Google Patents

Info

Publication number

JP2006512357A

JP2006512357A JP2004561828A JP2004561828A JP2006512357A JP 2006512357 A JP2006512357 A JP 2006512357A JP 2004561828 A JP2004561828 A JP 2004561828A JP 2004561828 A JP2004561828 A JP 2004561828A JP 2006512357 A JP2006512357 A JP 2006512357A

Authority

JP

Japan

Prior art keywords

alkyl

thioxo

dihydro

phenyl

thiazolidin

Prior art date

2002-12-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 108091007960 PI3Ks Proteins 0.000 title claims description 54
• 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title claims 3
• 239000003112 inhibitor Substances 0.000 title description 14
• CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 title description 3
• 150000001875 compounds Chemical class 0.000 claims abstract description 156
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
• 150000003839 salts Chemical class 0.000 claims abstract description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
• 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
• 229910052727 yttrium Inorganic materials 0.000 claims abstract description 3
• -1 4-pyridinyl Chemical group 0.000 claims description 154
• 125000000217 alkyl group Chemical group 0.000 claims description 38
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 37
• 208000035475 disorder Diseases 0.000 claims description 24
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
• 229910052739 hydrogen Inorganic materials 0.000 claims description 21
• 230000001404 mediated effect Effects 0.000 claims description 21
• 229910052799 carbon Inorganic materials 0.000 claims description 19
• 125000003342 alkenyl group Chemical group 0.000 claims description 16
• 125000000304 alkynyl group Chemical group 0.000 claims description 16
• 238000000034 method Methods 0.000 claims description 16
• 125000001624 naphthyl group Chemical group 0.000 claims description 15
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
• 239000005977 Ethylene Substances 0.000 claims description 13
• 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 9
• 125000001072 heteroaryl group Chemical group 0.000 claims description 9
• 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
• 229910052757 nitrogen Inorganic materials 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 229910052717 sulfur Inorganic materials 0.000 claims description 5
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 4
• 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims description 4
• 201000008482 osteoarthritis Diseases 0.000 claims description 4
• ADHBQTVRFHHGSD-UHFFFAOYSA-N phenyl 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxylate Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)OC1=CC=CC=C1 ADHBQTVRFHHGSD-UHFFFAOYSA-N 0.000 claims description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims description 4
• AZHNJGMAHPCYTO-UHFFFAOYSA-N (4-methoxycarbonylphenyl) 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxylate Chemical compound C1=CC(C(=O)OC)=CC=C1OC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 AZHNJGMAHPCYTO-UHFFFAOYSA-N 0.000 claims description 3
• SZJWGDUDJSGXGD-UHFFFAOYSA-N (4-methylphenyl) 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxylate Chemical compound C1=CC(C)=CC=C1OC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 SZJWGDUDJSGXGD-UHFFFAOYSA-N 0.000 claims description 3
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
• SCBNEBCVYMOMFL-UHFFFAOYSA-N 5-[(4-heptanoyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)CCCCCC)CCOC2=CC=C1C=C1SC(=S)NC1=O SCBNEBCVYMOMFL-UHFFFAOYSA-N 0.000 claims description 3
• PKHANDDFNUXAFV-UHFFFAOYSA-N 5-[(4-pentanoyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)CCCC)CCOC2=CC=C1C=C1SC(=S)NC1=O PKHANDDFNUXAFV-UHFFFAOYSA-N 0.000 claims description 3
• UWKBMECNTWQSLY-UHFFFAOYSA-N 5-[[4-(2-methylpropanoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)C(C)C)CCOC2=CC=C1C=C1SC(=S)NC1=O UWKBMECNTWQSLY-UHFFFAOYSA-N 0.000 claims description 3
• WFJYMLNJPHSLNA-UHFFFAOYSA-N 5-[[4-(2-phenylmethoxyacetyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)COCC1=CC=CC=C1 WFJYMLNJPHSLNA-UHFFFAOYSA-N 0.000 claims description 3
• LYJCNRVAIPWBKM-UHFFFAOYSA-N 5-[[4-(2-phenylsulfanylacetyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)CSC1=CC=CC=C1 LYJCNRVAIPWBKM-UHFFFAOYSA-N 0.000 claims description 3
• GMMCWLUTYRNKNT-UHFFFAOYSA-N 5-[[4-(3-cyclopentylpropanoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)CCC1CCCC1 GMMCWLUTYRNKNT-UHFFFAOYSA-N 0.000 claims description 3
• UBDWHOTZVUMAGD-UHFFFAOYSA-N 5-[[4-(3-phenylprop-2-enoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C=CC1=CC=CC=C1 UBDWHOTZVUMAGD-UHFFFAOYSA-N 0.000 claims description 3
• ABMAEMXZZIQZAW-UHFFFAOYSA-N 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-n-(2-phenylethyl)-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)NCCC1=CC=CC=C1 ABMAEMXZZIQZAW-UHFFFAOYSA-N 0.000 claims description 3
• BOJXKPUZPWUBKG-UHFFFAOYSA-N 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-n-[3-(trifluoromethyl)phenyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 BOJXKPUZPWUBKG-UHFFFAOYSA-N 0.000 claims description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
• 208000023275 Autoimmune disease Diseases 0.000 claims description 3
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 claims description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 3
• YMPZGWKUVRLVKJ-UHFFFAOYSA-N methyl 8-oxo-8-[6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazin-4-yl]octanoate Chemical compound C1=C2N(C(=O)CCCCCCC(=O)OC)CCOC2=CC=C1C=C1SC(=S)NC1=O YMPZGWKUVRLVKJ-UHFFFAOYSA-N 0.000 claims description 3
• GSMHWGJGKAOCFZ-UHFFFAOYSA-N n-(3-chlorophenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound ClC1=CC=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 GSMHWGJGKAOCFZ-UHFFFAOYSA-N 0.000 claims description 3
• OMCSAMOTVJTYBH-UHFFFAOYSA-N n-(4-chlorophenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 OMCSAMOTVJTYBH-UHFFFAOYSA-N 0.000 claims description 3
• KNTWQLFICXLUMJ-UHFFFAOYSA-N n-cyclopentyl-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)NC1CCCC1 KNTWQLFICXLUMJ-UHFFFAOYSA-N 0.000 claims description 3
• XSDJJZZCSAQENW-UHFFFAOYSA-N naphthalen-1-yl 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxylate Chemical compound C=1C=CC2=CC=CC=C2C=1OC(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O XSDJJZZCSAQENW-UHFFFAOYSA-N 0.000 claims description 3
• 125000004076 pyridyl group Chemical group 0.000 claims description 3
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
• 125000001544 thienyl group Chemical group 0.000 claims description 3
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
• NPGBBBUQVSTPBS-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 NPGBBBUQVSTPBS-UHFFFAOYSA-N 0.000 claims description 2
• BSTXURKZHUFJNL-UHFFFAOYSA-N n-(3,5-dimethylphenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound CC1=CC(C)=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 BSTXURKZHUFJNL-UHFFFAOYSA-N 0.000 claims description 2
• 201000010099 disease Diseases 0.000 abstract description 15
• 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
• 239000000126 substance Substances 0.000 abstract description 3
• 201000011529 cardiovascular cancer Diseases 0.000 abstract description 2
• 229910052700 potassium Inorganic materials 0.000 abstract description 2
• 239000000543 intermediate Substances 0.000 description 54
• 102000038030 PI3Ks Human genes 0.000 description 51
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 50
• 239000000203 mixture Substances 0.000 description 39
• 239000011541 reaction mixture Substances 0.000 description 37
• 239000000047 product Substances 0.000 description 32
• 238000004452 microanalysis Methods 0.000 description 31
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
• 239000000243 solution Substances 0.000 description 27
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
• 125000004432 carbon atom Chemical group C* 0.000 description 19
• 238000006243 chemical reaction Methods 0.000 description 18
• 125000000753 cycloalkyl group Chemical group 0.000 description 16
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 15
• 239000002253 acid Substances 0.000 description 15
• 210000004027 cell Anatomy 0.000 description 15
• FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
• 238000012360 testing method Methods 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 150000002632 lipids Chemical class 0.000 description 12
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
• 235000019341 magnesium sulphate Nutrition 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• 230000000694 effects Effects 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 239000012044 organic layer Substances 0.000 description 11
• 239000003826 tablet Substances 0.000 description 11
• 108091006027 G proteins Proteins 0.000 description 10
• 102000030782 GTP binding Human genes 0.000 description 10
• 108091000058 GTP-Binding Proteins 0.000 description 10
• 125000002252 acyl group Chemical group 0.000 description 10
• 239000012267 brine Substances 0.000 description 10
• 238000005259 measurement Methods 0.000 description 10
• 125000002950 monocyclic group Chemical group 0.000 description 10
• 229910000027 potassium carbonate Inorganic materials 0.000 description 10
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 125000003118 aryl group Chemical group 0.000 description 9
• 238000009833 condensation Methods 0.000 description 9
• 230000005494 condensation Effects 0.000 description 9
• 239000003814 drug Substances 0.000 description 9
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
• 239000011347 resin Substances 0.000 description 9
• 229920005989 resin Polymers 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 101710189301 101 kDa malaria antigen Proteins 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 206010028980 Neoplasm Diseases 0.000 description 8
• 102100026478 Phosphoinositide 3-kinase regulatory subunit 5 Human genes 0.000 description 8
• 201000011510 cancer Diseases 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 125000005842 heteroatom Chemical group 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 8
• 241000701447 unidentified baculovirus Species 0.000 description 8
• 125000003341 7 membered heterocyclic group Chemical group 0.000 description 7
• 150000001412 amines Chemical class 0.000 description 7
• 125000005343 heterocyclic alkyl group Chemical group 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 102000004169 proteins and genes Human genes 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 6
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 6
• 125000005330 8 membered heterocyclic group Chemical group 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000012948 isocyanate Substances 0.000 description 6
• 150000002513 isocyanates Chemical class 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000004454 trace mineral analysis Methods 0.000 description 6
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• 239000006180 TBST buffer Substances 0.000 description 5
• 125000003545 alkoxy group Chemical group 0.000 description 5
• 239000011324 bead Substances 0.000 description 5
• 239000012458 free base Substances 0.000 description 5
• WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 125000004430 oxygen atom Chemical group O* 0.000 description 5
• NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 5
• 229910000104 sodium hydride Inorganic materials 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 229920002261 Corn starch Polymers 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
• 108091000080 Phosphotransferase Proteins 0.000 description 4
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 150000001335 aliphatic alkanes Chemical class 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 239000003146 anticoagulant agent Substances 0.000 description 4
• HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 239000008120 corn starch Substances 0.000 description 4
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 150000007529 inorganic bases Chemical class 0.000 description 4
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
• 108010052968 leupeptin Proteins 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 102000020233 phosphotransferase Human genes 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 239000012312 sodium hydride Substances 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 230000002537 thrombolytic effect Effects 0.000 description 4
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
• QXDHXCVJGBTQMK-UHFFFAOYSA-N 1-(bromomethyl)-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(CBr)=C1 QXDHXCVJGBTQMK-UHFFFAOYSA-N 0.000 description 3
• JHRIPENGTGSNPJ-UHFFFAOYSA-N 2-amino-4-bromophenol Chemical compound NC1=CC(Br)=CC=C1O JHRIPENGTGSNPJ-UHFFFAOYSA-N 0.000 description 3
• QEJGMKHQXSZCOS-UHFFFAOYSA-N 2-naphthalen-2-ylacetyl chloride Chemical compound C1=CC=CC2=CC(CC(=O)Cl)=CC=C21 QEJGMKHQXSZCOS-UHFFFAOYSA-N 0.000 description 3
• GCSVNNODDIEGEX-UHFFFAOYSA-N 2-sulfanylidene-1,3-oxazolidin-4-one Chemical compound O=C1COC(=S)N1 GCSVNNODDIEGEX-UHFFFAOYSA-N 0.000 description 3
• VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 3
• 125000001627 3 membered heterocyclic group Chemical group 0.000 description 3
• 125000006186 3,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C([H])=C1C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 3
• 125000001963 4 membered heterocyclic group Chemical group 0.000 description 3
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 208000005189 Embolism Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
• 239000004793 Polystyrene Substances 0.000 description 3
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
• 229910000564 Raney nickel Inorganic materials 0.000 description 3
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
• 229940123464 Thiazolidinedione Drugs 0.000 description 3
• 208000001435 Thromboembolism Diseases 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 229960001138 acetylsalicylic acid Drugs 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 125000005233 alkylalcohol group Chemical group 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 3
• 125000001309 chloro group Chemical group Cl* 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 229940111134 coxibs Drugs 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 229910052744 lithium Inorganic materials 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 239000000693 micelle Substances 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
• 230000000269 nucleophilic effect Effects 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 125000004434 sulfur atom Chemical group 0.000 description 3
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
• 239000002562 thickening agent Substances 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
• OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 2
• VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
• XEFUJGURFLOFAN-UHFFFAOYSA-N 1,3-dichloro-5-isocyanatobenzene Chemical compound ClC1=CC(Cl)=CC(N=C=O)=C1 XEFUJGURFLOFAN-UHFFFAOYSA-N 0.000 description 2
• SNRYBGHMHAJTTM-UHFFFAOYSA-N 1-(bromomethyl)-3,5-ditert-butylbenzene Chemical compound CC(C)(C)C1=CC(CBr)=CC(C(C)(C)C)=C1 SNRYBGHMHAJTTM-UHFFFAOYSA-N 0.000 description 2
• HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 2
• ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 2
• DZSGDHNHQAJZCO-UHFFFAOYSA-N 1-isocyanato-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(N=C=O)=C1 DZSGDHNHQAJZCO-UHFFFAOYSA-N 0.000 description 2
• UZPDIOVMUOICPS-UHFFFAOYSA-N 2-(bromoamino)phenol Chemical compound OC1=CC=CC=C1NBr UZPDIOVMUOICPS-UHFFFAOYSA-N 0.000 description 2
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
• MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 2
• 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 2
• NYTBFFZQIRSGLL-UHFFFAOYSA-N 4-isocyanato-1,2-dimethoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1OC NYTBFFZQIRSGLL-UHFFFAOYSA-N 0.000 description 2
• ROMHMKLJFFKFJN-UHFFFAOYSA-N 5-[(4-benzoyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=CC=CC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O ROMHMKLJFFKFJN-UHFFFAOYSA-N 0.000 description 2
• CFRFXMKRMCIHNE-UHFFFAOYSA-N 5-[(4-benzoyl-3-methyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)C=3C=CC=CC=3)C(C)COC2=CC=C1C=C1SC(=S)NC1=O CFRFXMKRMCIHNE-UHFFFAOYSA-N 0.000 description 2
• JXZMZZKSKJWBQF-UHFFFAOYSA-N 5-[[4-[(3,5-dimethylphenyl)methyl]-3-methyl-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(CC=3C=C(C)C=C(C)C=3)C(C)COC2=CC=C1C=C1SC(=S)NC1=O JXZMZZKSKJWBQF-UHFFFAOYSA-N 0.000 description 2
• MNFPITABCLMULF-UHFFFAOYSA-N 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxylic acid Chemical compound C1=C2N(C(=O)O)CCOC2=CC=C1C=C1SC(=S)NC1=O MNFPITABCLMULF-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 206010002388 Angina unstable Diseases 0.000 description 2
• 108010039627 Aprotinin Proteins 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
• 206010051055 Deep vein thrombosis Diseases 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 239000005909 Kieselgur Substances 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 208000010378 Pulmonary Embolism Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 239000007868 Raney catalyst Substances 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000007814 Unstable Angina Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 206010047249 Venous thrombosis Diseases 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 150000001266 acyl halides Chemical class 0.000 description 2
• 229940009456 adriamycin Drugs 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 229940127218 antiplatelet drug Drugs 0.000 description 2
• 239000000010 aprotic solvent Substances 0.000 description 2
• 229960004405 aprotinin Drugs 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 229960001770 atorvastatin calcium Drugs 0.000 description 2
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
• 229960001671 azapropazone Drugs 0.000 description 2
• WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 2
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• 229940097320 beta blocking agent Drugs 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 229960000590 celecoxib Drugs 0.000 description 2
• 239000008004 cell lysis buffer Substances 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 239000013058 crude material Substances 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960001259 diclofenac Drugs 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• 229960001419 fenoprofen Drugs 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000003365 glass fiber Substances 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 229920002674 hyaluronan Polymers 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• 229960000991 ketoprofen Drugs 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 229940002661 lipitor Drugs 0.000 description 2
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
• 229960003464 mefenamic acid Drugs 0.000 description 2
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
• 229950000964 pepstatin Drugs 0.000 description 2
• 108010091212 pepstatin Proteins 0.000 description 2
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 229960002895 phenylbutazone Drugs 0.000 description 2
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229960002702 piroxicam Drugs 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 239000002798 polar solvent Substances 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
• 229960001233 pregabalin Drugs 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
• JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
• ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 2
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 229960000371 rofecoxib Drugs 0.000 description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
• 229960000894 sulindac Drugs 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• VHYZXADBMOZCLV-UHFFFAOYSA-N tert-butyl n-(5-bromo-2-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(Br)=CC=C1O VHYZXADBMOZCLV-UHFFFAOYSA-N 0.000 description 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 229960002004 valdecoxib Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• 239000008215 water for injection Substances 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
• RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
• MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
• OXOYYPFSKQLOCT-UHFFFAOYSA-N (4-methylphenyl) 7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxylate Chemical compound C1=CC(C)=CC=C1OC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 OXOYYPFSKQLOCT-UHFFFAOYSA-N 0.000 description 1
• XOFZPIYYMJUNRG-UHFFFAOYSA-N (4-methylphenyl) carbonochloridate Chemical compound CC1=CC=C(OC(Cl)=O)C=C1 XOFZPIYYMJUNRG-UHFFFAOYSA-N 0.000 description 1
• QJIMTLTYXBDJFC-UHFFFAOYSA-N (4-methylphenyl)-diphenylphosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJIMTLTYXBDJFC-UHFFFAOYSA-N 0.000 description 1
• 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
• DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
• 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• LPOQWSWPRAGSBK-UHFFFAOYSA-N 1,2-dibromo-3-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC(Br)=C1Br LPOQWSWPRAGSBK-UHFFFAOYSA-N 0.000 description 1
• PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
• HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
• DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• PXHFLWCSJYTAFU-UHFFFAOYSA-N 1,3-oxazolidin-4-one Chemical compound O=C1COCN1 PXHFLWCSJYTAFU-UHFFFAOYSA-N 0.000 description 1
• RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
• WRGKKASJBOREMB-UHFFFAOYSA-N 1,4-dibromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1Br WRGKKASJBOREMB-UHFFFAOYSA-N 0.000 description 1
• HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
• CCAWDIFJOBKBSE-UHFFFAOYSA-N 1-(chloromethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1 CCAWDIFJOBKBSE-UHFFFAOYSA-N 0.000 description 1
• ZEISGQRNZVCKOY-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,5-benzoxazepine-7-carbaldehyde Chemical compound O1CCCNC2=CC(C=O)=CC=C21 ZEISGQRNZVCKOY-UHFFFAOYSA-N 0.000 description 1
• JQNBCSPQVSUBSR-UHFFFAOYSA-N 2,3-dimethoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1OC JQNBCSPQVSUBSR-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• OQKWPJCAKRVADO-UHFFFAOYSA-N 2,5-dibromo-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC(Br)=CN=C1Br OQKWPJCAKRVADO-UHFFFAOYSA-N 0.000 description 1
• CJJURHKDGQSBLE-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C(Cl)=C1 CJJURHKDGQSBLE-UHFFFAOYSA-N 0.000 description 1
• BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
• JGRMXPSUZIYDRR-UHFFFAOYSA-N 2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)acetic acid Chemical compound OC(=O)CN1C(=O)CSC1=S JGRMXPSUZIYDRR-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
• LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
• DBTWOTKWIVISQR-UHFFFAOYSA-N 2-bromopropan-1-ol Chemical compound CC(Br)CO DBTWOTKWIVISQR-UHFFFAOYSA-N 0.000 description 1
• ITHKUADHDKZENI-UHFFFAOYSA-N 2-chloroethanethiol Chemical compound SCCCl ITHKUADHDKZENI-UHFFFAOYSA-N 0.000 description 1
• OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• RFTFYFUKANRPEK-UHFFFAOYSA-N 2-sulfanylidene-5-(2,3,4,5-tetrahydro-1,5-benzoxazepin-7-ylmethylidene)-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)SC1=CC1=CC=C(OCCCN2)C2=C1 RFTFYFUKANRPEK-UHFFFAOYSA-N 0.000 description 1
• OIZOBYZFOSBJLG-UHFFFAOYSA-N 2-sulfanylidene-5-[[4-(2-thiophen-2-ylacetyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)CC1=CC=CS1 OIZOBYZFOSBJLG-UHFFFAOYSA-N 0.000 description 1
• GFYCYWGUHRBSJF-UHFFFAOYSA-N 2-sulfanylidene-5-[[4-(3,4,5-trimethoxybenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 GFYCYWGUHRBSJF-UHFFFAOYSA-N 0.000 description 1
• SNFIAAZDKLTSIG-UHFFFAOYSA-N 2-sulfanylidene-5-[[4-(thiophene-2-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound C=1C=CSC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O SNFIAAZDKLTSIG-UHFFFAOYSA-N 0.000 description 1
• BBTJNUIAZSIKRY-UHFFFAOYSA-N 2-sulfanylidene-5-[[5-(2-thiophen-2-ylacetyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)CC1=CC=CS1 BBTJNUIAZSIKRY-UHFFFAOYSA-N 0.000 description 1
• 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
• 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
• QOJPAVNWONGHAR-UHFFFAOYSA-N 3,4-dibromo-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC=CC(Br)=C1Br QOJPAVNWONGHAR-UHFFFAOYSA-N 0.000 description 1
• MDLWSTPFRBDHQK-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine-6-carbaldehyde Chemical compound O1CCNC2=CC(C=O)=CC=C21 MDLWSTPFRBDHQK-UHFFFAOYSA-N 0.000 description 1
• YEEGQDGJIXWFIQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-oxazine Chemical compound C1COC=CN1 YEEGQDGJIXWFIQ-UHFFFAOYSA-N 0.000 description 1
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
• HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
• CKAMRIKMNPZNMZ-UHFFFAOYSA-N 3-amino-4-bromo-1h-pyridin-2-one Chemical class NC1=C(Br)C=CN=C1O CKAMRIKMNPZNMZ-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
• DVRWEKGUWZINTQ-UHFFFAOYSA-N 3-phenyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1CSC(=S)N1C1=CC=CC=C1 DVRWEKGUWZINTQ-UHFFFAOYSA-N 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• CSJBEDVFPBTAEP-UHFFFAOYSA-N 3-sulfonyl-4h-1,2-benzoxazine Chemical class C1=CC=C2ONC(=S(=O)=O)CC2=C1 CSJBEDVFPBTAEP-UHFFFAOYSA-N 0.000 description 1
• JXFRMELLZNBROJ-UHFFFAOYSA-N 4-(2-naphthalen-2-yl-2-oxoethyl)-2,3-dihydro-1,4-benzoxazine-6-carbaldehyde Chemical compound C1=CC=CC2=CC(C(=O)CN3CCOC4=CC=C(C=C43)C=O)=CC=C21 JXFRMELLZNBROJ-UHFFFAOYSA-N 0.000 description 1
• ZIWKQEZQQARYEI-UHFFFAOYSA-N 4-[(3,5-dimethylphenyl)methyl]-2,3-dihydro-1,4-benzoxazine-6-carbaldehyde Chemical compound CC1=CC(C)=CC(CN2C3=CC(C=O)=CC=C3OCC2)=C1 ZIWKQEZQQARYEI-UHFFFAOYSA-N 0.000 description 1
• PRSVYZIGTDXCIY-UHFFFAOYSA-N 4-[(3,5-ditert-butylphenyl)methyl]-2,3-dihydro-1,4-benzoxazine-6-carbaldehyde Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(CN2C3=CC(C=O)=CC=C3OCC2)=C1 PRSVYZIGTDXCIY-UHFFFAOYSA-N 0.000 description 1
• YWKCHSGJRXBSSC-UHFFFAOYSA-N 4-[2-(3,4-dichlorophenyl)acetyl]-2,3-dihydro-1,4-benzoxazine-6-carbaldehyde Chemical compound C1=C(Cl)C(Cl)=CC=C1CC(=O)N1C2=CC(C=O)=CC=C2OCC1 YWKCHSGJRXBSSC-UHFFFAOYSA-N 0.000 description 1
• BUGFTSIAUMZZAG-UHFFFAOYSA-N 4-[6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carbonyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O BUGFTSIAUMZZAG-UHFFFAOYSA-N 0.000 description 1
• UPIIQWWPMNZQOP-UHFFFAOYSA-N 4-[7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carbonyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)N(C1=C2)CCCOC1=CC=C2C=C1SC(=S)NC1=O UPIIQWWPMNZQOP-UHFFFAOYSA-N 0.000 description 1
• KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
• KLLJMWFZQNLGAP-UHFFFAOYSA-N 4-bromo-1-(2-chloroethylsulfanyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1SCCCl KLLJMWFZQNLGAP-UHFFFAOYSA-N 0.000 description 1
• ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical class NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
• CUTFAPGINUFNQM-UHFFFAOYSA-N 4-bromo-2-nitrophenol Chemical compound OC1=CC=C(Br)C=C1[N+]([O-])=O CUTFAPGINUFNQM-UHFFFAOYSA-N 0.000 description 1
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• IPEIDGXNXFPGBG-UHFFFAOYSA-N 4-methylsulfonylbenzoyl chloride Chemical compound CS(=O)(=O)C1=CC=C(C(Cl)=O)C=C1 IPEIDGXNXFPGBG-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
• QDUHQAQMOAHLRW-UHFFFAOYSA-N 4h-1,4-benzoxazine Chemical compound C1=CC=C2NC=COC2=C1 QDUHQAQMOAHLRW-UHFFFAOYSA-N 0.000 description 1
• ZPJCJTUWDUOCHC-UHFFFAOYSA-N 5-(2-phenylethyl)-3,4-dihydro-2h-1,5-benzoxazepine-7-carbaldehyde Chemical compound C12=CC(C=O)=CC=C2OCCCN1CCC1=CC=CC=C1 ZPJCJTUWDUOCHC-UHFFFAOYSA-N 0.000 description 1
• SRYZDGJWIONRHT-UHFFFAOYSA-N 5-(3,4-dihydro-2h-1,4-benzoxazin-6-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)SC1=CC1=CC=C(OCCN2)C2=C1 SRYZDGJWIONRHT-UHFFFAOYSA-N 0.000 description 1
• PLQBWTXWTIIKTN-UHFFFAOYSA-N 5-[(3,5-dimethoxyphenyl)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-7-carbaldehyde Chemical compound COC1=CC(OC)=CC(CN2C3=CC(C=O)=CC=C3OCCC2)=C1 PLQBWTXWTIIKTN-UHFFFAOYSA-N 0.000 description 1
• XZHRKFSZMSBVJD-UHFFFAOYSA-N 5-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-7-carbaldehyde Chemical compound CC1=CC(C)=CC(CN2C3=CC(C=O)=CC=C3OCCC2)=C1 XZHRKFSZMSBVJD-UHFFFAOYSA-N 0.000 description 1
• PWQIWGHWIHRWQH-UHFFFAOYSA-N 5-[(4-acetyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)C)CCOC2=CC=C1C=C1SC(=S)NC1=O PWQIWGHWIHRWQH-UHFFFAOYSA-N 0.000 description 1
• IOXMIAQUKUFNSU-UHFFFAOYSA-N 5-[(4-butanoyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)CCC)CCOC2=CC=C1C=C1SC(=S)NC1=O IOXMIAQUKUFNSU-UHFFFAOYSA-N 0.000 description 1
• JHTBZZKOZWNHOG-UHFFFAOYSA-N 5-[(4-hexanoyl-2,3-dihydro-1,4-benzoxazin-6-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)CCCCC)CCOC2=CC=C1C=C1SC(=S)NC1=O JHTBZZKOZWNHOG-UHFFFAOYSA-N 0.000 description 1
• KFHYPLKYBLMPOI-UHFFFAOYSA-N 5-[[4-(1,2-oxazole-5-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=NOC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O KFHYPLKYBLMPOI-UHFFFAOYSA-N 0.000 description 1
• UTTPQAZCCZILKX-UHFFFAOYSA-N 5-[[4-(1,3-benzodioxole-5-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C2OCOC2=CC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O UTTPQAZCCZILKX-UHFFFAOYSA-N 0.000 description 1
• PXDZFYZOHQDRCK-UHFFFAOYSA-N 5-[[4-(1-acetylpiperidine-4-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1CN(C(=O)C)CCC1C(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 PXDZFYZOHQDRCK-UHFFFAOYSA-N 0.000 description 1
• BSTQPYTXLPMWAB-UHFFFAOYSA-N 5-[[4-(2,1,3-benzoxadiazole-5-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC2=NON=C2C=C1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O BSTQPYTXLPMWAB-UHFFFAOYSA-N 0.000 description 1
• NIBBPQSRSQWDTA-UHFFFAOYSA-N 5-[[4-(2,2-difluoro-1,3-benzodioxole-5-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2OC(F)(F)OC2=CC=C1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O NIBBPQSRSQWDTA-UHFFFAOYSA-N 0.000 description 1
• NVTXXKPLUZXTKD-UHFFFAOYSA-N 5-[[4-(2,2-dimethylpropanoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)C(C)(C)C)CCOC2=CC=C1C=C1SC(=S)NC1=O NVTXXKPLUZXTKD-UHFFFAOYSA-N 0.000 description 1
• LFABLCZVSDLRKO-UHFFFAOYSA-N 5-[[4-(2,5-dichlorothiophene-3-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound S1C(Cl)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1Cl LFABLCZVSDLRKO-UHFFFAOYSA-N 0.000 description 1
• WHVVJKDPFRPXCQ-UHFFFAOYSA-N 5-[[4-(2-ethylhexanoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C2N(C(=O)C(CC)CCCC)CCOC2=CC=C1C=C1SC(=S)NC1=O WHVVJKDPFRPXCQ-UHFFFAOYSA-N 0.000 description 1
• CWKHBOFDVMIRHZ-UHFFFAOYSA-N 5-[[4-(2-naphthalen-2-ylacetyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C2C=CC=CC2=CC=1CC(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O CWKHBOFDVMIRHZ-UHFFFAOYSA-N 0.000 description 1
• TVZVKAZLTRHWGM-UHFFFAOYSA-N 5-[[4-(2-phenoxyacetyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)COC1=CC=CC=C1 TVZVKAZLTRHWGM-UHFFFAOYSA-N 0.000 description 1
• BUJSAWUBSNZZEL-UHFFFAOYSA-N 5-[[4-(2-phenylacetyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)CC1=CC=CC=C1 BUJSAWUBSNZZEL-UHFFFAOYSA-N 0.000 description 1
• XSENCPHPJGJUOV-UHFFFAOYSA-N 5-[[4-(2-phenylbutanoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=CC=CC=1C(CC)C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O XSENCPHPJGJUOV-UHFFFAOYSA-N 0.000 description 1
• CUKYGVLFBAYQIF-UHFFFAOYSA-N 5-[[4-(3,5-dichlorobenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC1=CC(Cl)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 CUKYGVLFBAYQIF-UHFFFAOYSA-N 0.000 description 1
• NNOQZEDIMUDZMT-UHFFFAOYSA-N 5-[[4-(3,5-difluorobenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound FC1=CC(F)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 NNOQZEDIMUDZMT-UHFFFAOYSA-N 0.000 description 1
• XVJIERXVATWQAT-UHFFFAOYSA-N 5-[[4-(3-chlorothiophene-2-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CSC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1Cl XVJIERXVATWQAT-UHFFFAOYSA-N 0.000 description 1
• ZRNGQKWAROBRFT-UHFFFAOYSA-N 5-[[4-(3-methoxybenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound COC1=CC=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 ZRNGQKWAROBRFT-UHFFFAOYSA-N 0.000 description 1
• GHOKVOXQVQEULE-UHFFFAOYSA-N 5-[[4-(3-methylbenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CC1=CC=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 GHOKVOXQVQEULE-UHFFFAOYSA-N 0.000 description 1
• DBFWDGJKBLJFPP-UHFFFAOYSA-N 5-[[4-(3-phenylpropanoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)CCC1=CC=CC=C1 DBFWDGJKBLJFPP-UHFFFAOYSA-N 0.000 description 1
• ZQNWKMNSWRUYRW-UHFFFAOYSA-N 5-[[4-(4-ethylbenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(CC)=CC=C1C(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 ZQNWKMNSWRUYRW-UHFFFAOYSA-N 0.000 description 1
• VOQQOUJLGNGMHT-UHFFFAOYSA-N 5-[[4-(4-hexylbenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(CCCCCC)=CC=C1C(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 VOQQOUJLGNGMHT-UHFFFAOYSA-N 0.000 description 1
• KVHMUXNOEJOUFO-UHFFFAOYSA-N 5-[[4-(4-phenylbenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O KVHMUXNOEJOUFO-UHFFFAOYSA-N 0.000 description 1
• VFAUMFYBAZQIEV-UHFFFAOYSA-N 5-[[4-(4-tert-butylbenzoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 VFAUMFYBAZQIEV-UHFFFAOYSA-N 0.000 description 1
• GASJFEBTVJTCCY-UHFFFAOYSA-N 5-[[4-(5-methyl-1,2-oxazole-3-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O1C(C)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=N1 GASJFEBTVJTCCY-UHFFFAOYSA-N 0.000 description 1
• NCFUXDCPXHWSQA-UHFFFAOYSA-N 5-[[4-(cyclohexanecarbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C1CCCCC1 NCFUXDCPXHWSQA-UHFFFAOYSA-N 0.000 description 1
• SZYUFCCYVPAAOY-UHFFFAOYSA-N 5-[[4-(cyclopentanecarbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C1CCCC1 SZYUFCCYVPAAOY-UHFFFAOYSA-N 0.000 description 1
• PTNBUXGQSOMMNN-UHFFFAOYSA-N 5-[[4-(cyclopropanecarbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C1CC1 PTNBUXGQSOMMNN-UHFFFAOYSA-N 0.000 description 1
• DWCWLESODLMURO-UHFFFAOYSA-N 5-[[4-(furan-2-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=COC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O DWCWLESODLMURO-UHFFFAOYSA-N 0.000 description 1
• XVURDGDGZMGVHP-UHFFFAOYSA-N 5-[[4-(naphthalene-2-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O XVURDGDGZMGVHP-UHFFFAOYSA-N 0.000 description 1
• PFYWVSSSTIXJSO-UHFFFAOYSA-N 5-[[4-(pyridine-2-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=CC=NC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O PFYWVSSSTIXJSO-UHFFFAOYSA-N 0.000 description 1
• IFUALFQLTAOOIF-UHFFFAOYSA-N 5-[[4-(quinoxaline-2-carbonyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1N=C2C=CC=CC2=NC=1C(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O IFUALFQLTAOOIF-UHFFFAOYSA-N 0.000 description 1
• LJBHWLJGORNXMY-UHFFFAOYSA-N 5-[[4-[(7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl)methylsulfonyl]-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CC1(C)C(CC2=O)CCC12CS(=O)(=O)N(C1=C2)CCOC1=CC=C2C=C1SC(=S)NC1=O LJBHWLJGORNXMY-UHFFFAOYSA-N 0.000 description 1
• OFQHTPVZSDKCDS-UHFFFAOYSA-N 5-[[4-[2-(3,4-dimethoxyphenyl)acetyl]-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 OFQHTPVZSDKCDS-UHFFFAOYSA-N 0.000 description 1
• DJWJYPCFJAAVRB-UHFFFAOYSA-N 5-[[4-[2-(4-chlorophenoxy)acetyl]-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(Cl)=CC=C1OCC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 DJWJYPCFJAAVRB-UHFFFAOYSA-N 0.000 description 1
• YTCRJYNUWIGWHA-UHFFFAOYSA-N 5-[[4-[3,5-bis(trifluoromethyl)benzoyl]-2,3-dihydro-1,4-benzoxazin-6-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 YTCRJYNUWIGWHA-UHFFFAOYSA-N 0.000 description 1
• ONSZFAFBBYGVLU-UHFFFAOYSA-N 5-[[5-(2,1,3-benzoxadiazole-5-carbonyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC2=NON=C2C=C1C(=O)N(C1=C2)CCCOC1=CC=C2C=C1SC(=S)NC1=O ONSZFAFBBYGVLU-UHFFFAOYSA-N 0.000 description 1
• DXEMRKJHCOZLQH-UHFFFAOYSA-N 5-[[5-(2-phenylmethoxyacetyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)COCC1=CC=CC=C1 DXEMRKJHCOZLQH-UHFFFAOYSA-N 0.000 description 1
• DEKYKUZIURYXMO-UHFFFAOYSA-N 5-[[5-(3,4-dichlorobenzoyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 DEKYKUZIURYXMO-UHFFFAOYSA-N 0.000 description 1
• RMYIRPIKZKOCFR-UHFFFAOYSA-N 5-[[5-(3-phenylprop-2-enoyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C=CC1=CC=CC=C1 RMYIRPIKZKOCFR-UHFFFAOYSA-N 0.000 description 1
• JRTWPXFOAQDBJQ-UHFFFAOYSA-N 5-[[5-(4-hexylbenzoyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(CCCCCC)=CC=C1C(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 JRTWPXFOAQDBJQ-UHFFFAOYSA-N 0.000 description 1
• STPCFGMQMDHZMX-UHFFFAOYSA-N 5-[[5-(5-tert-butyl-2-methylfuran-3-carbonyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O1C(C(C)(C)C)=CC(C(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCCC2)=C1C STPCFGMQMDHZMX-UHFFFAOYSA-N 0.000 description 1
• HQOHBGRMKNRKBO-UHFFFAOYSA-N 5-[[5-(cyclopentanecarbonyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C1CCCC1 HQOHBGRMKNRKBO-UHFFFAOYSA-N 0.000 description 1
• MQSQHHRFZGEUCV-UHFFFAOYSA-N 5-[[5-(cyclopropanecarbonyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)C1CC1 MQSQHHRFZGEUCV-UHFFFAOYSA-N 0.000 description 1
• NXAKLFUCFNTOSJ-UHFFFAOYSA-N 5-[[5-(furan-2-carbonyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=COC=1C(=O)N(C1=C2)CCCOC1=CC=C2C=C1SC(=S)NC1=O NXAKLFUCFNTOSJ-UHFFFAOYSA-N 0.000 description 1
• GYIKNYJZRWHTIS-UHFFFAOYSA-N 5-[[5-(pyridine-3-carbonyl)-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=CN=CC=1C(=O)N(C1=C2)CCCOC1=CC=C2C=C1SC(=S)NC1=O GYIKNYJZRWHTIS-UHFFFAOYSA-N 0.000 description 1
• WYYVRDBOYHNNNK-UHFFFAOYSA-N 5-[[5-[(3,5-dimethoxyphenyl)methyl]-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound COC1=CC(OC)=CC(CN2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCCC2)=C1 WYYVRDBOYHNNNK-UHFFFAOYSA-N 0.000 description 1
• OFOMRSXAMOBIIU-UHFFFAOYSA-N 5-[[5-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CC1=CC(C)=CC(CN2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCCC2)=C1 OFOMRSXAMOBIIU-UHFFFAOYSA-N 0.000 description 1
• QCMUZXHXQLIIAL-UHFFFAOYSA-N 5-[[5-[2-(4-chlorophenoxy)acetyl]-3,4-dihydro-2h-1,5-benzoxazepin-7-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(Cl)=CC=C1OCC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 QCMUZXHXQLIIAL-UHFFFAOYSA-N 0.000 description 1
• QOOCOFOGYRQPPN-UHFFFAOYSA-N 5-bromo-3-nitropyridin-2-amine Chemical class NC1=NC=C(Br)C=C1[N+]([O-])=O QOOCOFOGYRQPPN-UHFFFAOYSA-N 0.000 description 1
• XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
• LGOSDUGPTLNHHO-UHFFFAOYSA-N 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-n-(4-phenoxyphenyl)-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 LGOSDUGPTLNHHO-UHFFFAOYSA-N 0.000 description 1
• JHKPFQBJRPZTIH-UHFFFAOYSA-N 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-n-[2-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical class FC(F)(F)OC1=CC=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 JHKPFQBJRPZTIH-UHFFFAOYSA-N 0.000 description 1
• WQADFDMPUFTBGS-UHFFFAOYSA-N 6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-n-phenyl-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1COC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)NC1=CC=CC=C1 WQADFDMPUFTBGS-UHFFFAOYSA-N 0.000 description 1
• LAFDIAAHRWZORH-UHFFFAOYSA-N 6-bromo-3-methyl-2,3-dihydro-1,4-benzoxazine-4-carboxylic acid Chemical compound C1=C(Br)C=C2N(C(O)=O)C(C)COC2=C1 LAFDIAAHRWZORH-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• TXTRWOFQAGTKBT-UHFFFAOYSA-N 7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-n-(4-phenoxyphenyl)-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxamide Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 TXTRWOFQAGTKBT-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102400000069 Activation peptide Human genes 0.000 description 1
• 101800001401 Activation peptide Proteins 0.000 description 1
• 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 102000012936 Angiostatins Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 229940127398 Angiotensin 2 Receptor Antagonists Drugs 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000004342 Benzoyl peroxide Substances 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• RKYAFWRXPSZTHG-UHFFFAOYSA-N C1=CC(C(=O)OC)=CC=C1OC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 Chemical compound C1=CC(C(=O)OC)=CC=C1OC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 RKYAFWRXPSZTHG-UHFFFAOYSA-N 0.000 description 1
• FUHRASOZOGWRHC-UHFFFAOYSA-N C1=CC=C(C=C1)S(=O)(=O)C(=C1C(NC(S1)=S)=O)C=1C=CC2=C(NCCO2)C1 Chemical compound C1=CC=C(C=C1)S(=O)(=O)C(=C1C(NC(S1)=S)=O)C=1C=CC2=C(NCCO2)C1 FUHRASOZOGWRHC-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 102100027995 Collagenase 3 Human genes 0.000 description 1
• 108050005238 Collagenase 3 Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 102400001047 Endostatin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 210000000712 G cell Anatomy 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 101001092933 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Phosphatidylinositol-3-phosphatase Proteins 0.000 description 1
• WQUVVJGQCJRRPH-UHFFFAOYSA-N N-(3,4-dimethoxyphenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 WQUVVJGQCJRRPH-UHFFFAOYSA-N 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
• 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
• 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004721 Polyphenylene oxide Substances 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• KYOIPUDHYRWSFO-UHFFFAOYSA-N [Br].[Li] Chemical group [Br].[Li] KYOIPUDHYRWSFO-UHFFFAOYSA-N 0.000 description 1
• SAIFTDNQIARTIU-UHFFFAOYSA-N [N].CCC Chemical compound [N].CCC SAIFTDNQIARTIU-UHFFFAOYSA-N 0.000 description 1
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• DPRMFUAMSRXGDE-UHFFFAOYSA-N ac1o530g Chemical compound NCCN.NCCN DPRMFUAMSRXGDE-UHFFFAOYSA-N 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000005273 aeration Methods 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
• 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 125000004450 alkenylene group Chemical group 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• 125000005741 alkyl alkenyl group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 150000001356 alkyl thiols Chemical class 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000007131 anti Alzheimer effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002421 anti-septic effect Effects 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000000939 antiparkinson agent Substances 0.000 description 1
• 229940125688 antiparkinson agent Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 229960002274 atenolol Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
• 229960005207 auranofin Drugs 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
• 239000003899 bactericide agent Substances 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 229940110331 bextra Drugs 0.000 description 1
• 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
• BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 229910000085 borane Inorganic materials 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229960003958 clopidogrel bisulfate Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• 229940125878 compound 36 Drugs 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940066901 crestor Drugs 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 229940075933 dithionate Drugs 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 239000008393 encapsulating agent Substances 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 229960004945 etoricoxib Drugs 0.000 description 1
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229940085363 evista Drugs 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 229960004396 famciclovir Drugs 0.000 description 1
• GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 229940018991 hyalgan Drugs 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 229940071870 hydroiodic acid Drugs 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 208000023589 ischemic disease Diseases 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• ILFYJFZENXEOBT-UHFFFAOYSA-N isocyanatobenzene Chemical compound O=C=NC1=CC=CC=C1.O=C=NC1=CC=CC=C1 ILFYJFZENXEOBT-UHFFFAOYSA-N 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 229940054136 kineret Drugs 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• PPVBQEZMYRAXPV-UHFFFAOYSA-N methyl 4-carbonochloridoyloxybenzoate Chemical compound COC(=O)C1=CC=C(OC(Cl)=O)C=C1 PPVBQEZMYRAXPV-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 229960001952 metrifonate Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229940101972 mirapex Drugs 0.000 description 1
• 239000011812 mixed powder Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• FGOPZQVHCAKWSQ-UHFFFAOYSA-N n-(3,5-dimethoxyphenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical class COC1=CC(OC)=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 FGOPZQVHCAKWSQ-UHFFFAOYSA-N 0.000 description 1
• UKSUQEMLKRSJLJ-UHFFFAOYSA-N n-(3,5-dimethoxyphenyl)-7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxamide Chemical compound COC1=CC(OC)=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCCC2)=C1 UKSUQEMLKRSJLJ-UHFFFAOYSA-N 0.000 description 1
• VCHGURCWKRVNSQ-UHFFFAOYSA-N n-(3-methoxyphenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCC2)=C1 VCHGURCWKRVNSQ-UHFFFAOYSA-N 0.000 description 1
• VVMAYMOMSGRCTL-UHFFFAOYSA-N n-(3-methoxyphenyl)-7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2C3=CC(C=C4C(NC(=S)S4)=O)=CC=C3OCCC2)=C1 VVMAYMOMSGRCTL-UHFFFAOYSA-N 0.000 description 1
• SBZVNIPUHHMCLP-UHFFFAOYSA-N n-(4-methylphenyl)-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCC1 SBZVNIPUHHMCLP-UHFFFAOYSA-N 0.000 description 1
• AFSLMRRKKJFEDW-UHFFFAOYSA-N n-(4-methylphenyl)-7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 AFSLMRRKKJFEDW-UHFFFAOYSA-N 0.000 description 1
• WUIRPXPIMSMTRM-UHFFFAOYSA-N n-[4-chloro-2-(trifluoromethyl)phenyl]-7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxamide Chemical compound FC(F)(F)C1=CC(Cl)=CC=C1NC(=O)N1C2=CC(C=C3C(NC(=S)S3)=O)=CC=C2OCCC1 WUIRPXPIMSMTRM-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• FXVNDCORCIHVST-UHFFFAOYSA-N n-octyl-6-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound C1=C2N(C(=O)NCCCCCCCC)CCOC2=CC=C1C=C1SC(=S)NC1=O FXVNDCORCIHVST-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• VPIZZTUHFUJBDJ-UHFFFAOYSA-N naphthalen-1-yl 7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxylate Chemical compound C=1C=CC2=CC=CC=C2C=1OC(=O)N(C1=C2)CCCOC1=CC=C2C=C1SC(=S)NC1=O VPIZZTUHFUJBDJ-UHFFFAOYSA-N 0.000 description 1
• JRUFQZPDRRGHEF-UHFFFAOYSA-N naphthalen-1-yl carbonochloridate Chemical compound C1=CC=C2C(OC(=O)Cl)=CC=CC2=C1 JRUFQZPDRRGHEF-UHFFFAOYSA-N 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940036132 norvasc Drugs 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003551 oxepanyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006201 parenteral dosage form Substances 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000003444 phase transfer catalyst Substances 0.000 description 1
• OKLIXWQFVPTURO-UHFFFAOYSA-N phenyl 7-[(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]-3,4-dihydro-2h-1,5-benzoxazepine-5-carboxylate Chemical compound C1CCOC2=CC=C(C=C3C(NC(=S)S3)=O)C=C2N1C(=O)OC1=CC=CC=C1 OKLIXWQFVPTURO-UHFFFAOYSA-N 0.000 description 1
• AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229940020573 plavix Drugs 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 150000004672 propanoic acids Chemical class 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 229960002119 raloxifene hydrochloride Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
• 229960000245 rasagiline Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 229940113775 requip Drugs 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 229940116351 sebacate Drugs 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 1
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• 125000005415 substituted alkoxy group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000003461 sulfonyl halides Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
• 229960001685 tacrine Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229940000238 tasmar Drugs 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001583 thiepanyl group Chemical group 0.000 description 1
• 125000002053 thietanyl group Chemical group 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 125000005503 thioxanyl group Chemical group 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
• MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
• 125000005455 trithianyl group Chemical group 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1